Summary
468.88 -3.63(-0.77%)06/28/2024
Vertex Pharmaceuticals, Inc. (VRTX)
Vertex Pharmaceuticals, Inc. (VRTX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.76 | 0.05 | 5.00 | 12.05 | 14.55 | 33.67 | 155.69 | 10,319.56 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 468.88 | |
| Open | 473.21 | |
| High | 477.31 | |
| Low | 467.79 | |
| Volume | 958,056 | |
| Change | -3.57 | |
| Change % | -0.76 | |
| Avg Volume (20 Days) | 851,113 | |
| Volume/Avg Volume (20 Days) Ratio | 1.13 | |
| 52 Week Range | 335.82 - 486.43 | |
| Price vs 52 Week High | -3.61% | |
| Price vs 52 Week Low | 39.62% | |
| Range | -0.92 | |
| Gap Up/Down | -4.63 | |
Fundamentals | ||
| Market Capitalization (Mln) | 120,955 | |
| EBIDTA | 2,770,692,096 | |
| PE Ratio | 25.0947 | |
| PEG Ratio | 0.3183 | |
| WallStreet Target Price | 255.61 | |
| Book Value | 37.1990 | |
| Earnings Per Share | 8.3380 | |
| EPS Estimate Current Quarter | 3.0800 | |
| EPS Estimate Next Quarter | 3.1800 | |
| EPS Estimate Current Year | 12.7500 | |
| EPS Estimate Next Year | 13.5100 | |
| Diluted EPS (TTM) | 8.3380 | |
| Revenues | ||
| Profit Marging | 0.3052 | |
| Operating Marging (TTM) | 0.3716 | |
| Return on asset (TTM) | 0.1385 | |
| Return on equity (TTM) | 0.2464 | |
| Revenue TTM | 7,129,658,880 | |
| Revenue per share TTM | 27.5640 | |
| Quarterly Revenue Growth (YOY) | 0.2900 | |
| Quarterly Earnings Growth (YOY) | 0.2960 | |
| Gross Profit (TTM) | 3,639,846,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 25.0947 | |
| Forward PE | 15.7729 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 5.5504 | |
| Revenue Enterprise Value | 6.5663 | |
| EBITDA Enterprise Value | 15.9677 | |
| Shares | ||
| Shares Outstanding | 254,252,000 | |
| Shares Float | 253,674,786 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.16 | |
| Institutions (%) | 93.62 | |
06/28 07:45 EST - fool.com
2 Superior Growth Stocks to Buy if You Have $1,000 Right Now
The rare disease drug industry is fast-growing, while the music streaming space is also expanding at a rapid clip. Vertex is raking in profits from its cystic fibrosis drug franchise, but is also planning new additions to its portfolio.
2 Superior Growth Stocks to Buy if You Have $1,000 Right Now
The rare disease drug industry is fast-growing, while the music streaming space is also expanding at a rapid clip. Vertex is raking in profits from its cystic fibrosis drug franchise, but is also planning new additions to its portfolio.
06/28 05:50 EST - fool.com
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
Vertex Pharmaceuticals could have multiple new blockbusters on the way. Viking Therapeutics is targeting two massive markets -- obesity and NASH.
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
Vertex Pharmaceuticals could have multiple new blockbusters on the way. Viking Therapeutics is targeting two massive markets -- obesity and NASH.
06/28 03:31 EST - fool.com
2 Healthcare Stocks That Are Screaming Buys in June
A rare-disease drugmaker and a top pharmaceutical stock have what it takes to deliver solid returns over the long run. Vertex Pharmaceuticals' flagship business continues to expand market share and profits.
2 Healthcare Stocks That Are Screaming Buys in June
A rare-disease drugmaker and a top pharmaceutical stock have what it takes to deliver solid returns over the long run. Vertex Pharmaceuticals' flagship business continues to expand market share and profits.
06/27 10:55 EST - zacks.com
Vertex (VRTX) Rises 16.5% YTD: Time to Bet On the Stock?
While CF remains the main area of focus, Vertex (VRTX) has seen rapid success in its non-CF pipeline candidates' development in the past year.
Vertex (VRTX) Rises 16.5% YTD: Time to Bet On the Stock?
While CF remains the main area of focus, Vertex (VRTX) has seen rapid success in its non-CF pipeline candidates' development in the past year.
06/27 08:41 EST - benzinga.com
This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
06/27 06:40 EST - investorplace.com
3 Biotech Stocks That Could Make Your Grandchildren Rich
In the world of investing, biotech stocks represent a unique blend of high risk and high reward. After a period of volatility in the broader markets in 2022 and 2023, biotech stocks are now drawing attention for their potential to deliver substantial long-term returns.
3 Biotech Stocks That Could Make Your Grandchildren Rich
In the world of investing, biotech stocks represent a unique blend of high risk and high reward. After a period of volatility in the broader markets in 2022 and 2023, biotech stocks are now drawing attention for their potential to deliver substantial long-term returns.
06/26 10:05 EST - zacks.com
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
06/25 04:12 EST - fool.com
Everyone's Talking About Vertex Pharmaceuticals. Is It Time to Buy?
Vertex Pharmaceuticals recently turned heads with clinical trial results for VX-880, an off-the-shelf cellular therapy for type 1 diabetes patients. Treatment with VX-880 helped patients produce insulin independently and reduced their reliance on daily injections.
Everyone's Talking About Vertex Pharmaceuticals. Is It Time to Buy?
Vertex Pharmaceuticals recently turned heads with clinical trial results for VX-880, an off-the-shelf cellular therapy for type 1 diabetes patients. Treatment with VX-880 helped patients produce insulin independently and reduced their reliance on daily injections.
06/24 19:05 EST - zacks.com
Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note
Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $474.95, signifying a +1.33% move from its prior day's close.
Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note
Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $474.95, signifying a +1.33% move from its prior day's close.
06/24 10:50 EST - zacks.com
Here's Why Vertex Pharmaceuticals (VRTX) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Vertex Pharmaceuticals (VRTX) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
06/21 15:45 EST - businesswire.com
Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented new data from its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). These updated data on 12 patients who received the full dose as a single infusion in Parts B and C of the trial are consistent with previously reported positive.
Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented new data from its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). These updated data on 12 patients who received the full dose as a single infusion in Parts B and C of the trial are consistent with previously reported positive.
06/21 05:51 EST - fool.com
Forget Eli Lilly, Buy This Magnificent Biotech Stock Instead
This magnificent drugmaker is much smaller than Eli Lilly, but is still large and successful. It has massive growth opportunities in multiple markets.
Forget Eli Lilly, Buy This Magnificent Biotech Stock Instead
This magnificent drugmaker is much smaller than Eli Lilly, but is still large and successful. It has massive growth opportunities in multiple markets.
06/18 19:05 EST - zacks.com
Vertex Pharmaceuticals (VRTX) Stock Dips While Market Gains: Key Facts
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $467.28, indicating a -1.35% shift from the previous trading day.
Vertex Pharmaceuticals (VRTX) Stock Dips While Market Gains: Key Facts
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $467.28, indicating a -1.35% shift from the previous trading day.
06/18 06:50 EST - fool.com
3 Top Stocks I'd Buy Today and Hold Forever Without Any Hesitation
Vertex Pharmaceuticals has a lock on its market, generating funds for its R&D pipeline. Costco Wholesale is a near-perfect fit for its market.
3 Top Stocks I'd Buy Today and Hold Forever Without Any Hesitation
Vertex Pharmaceuticals has a lock on its market, generating funds for its R&D pipeline. Costco Wholesale is a near-perfect fit for its market.
06/15 06:50 EST - fool.com
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Eli Lilly appears to be on course to become the first trillion-dollar healthcare stock. Novo Nordisk is one of the best ways to profit from the fast-growing obesity drug market.
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Eli Lilly appears to be on course to become the first trillion-dollar healthcare stock. Novo Nordisk is one of the best ways to profit from the fast-growing obesity drug market.
06/14 13:29 EST - youtube.com
Final Trades: Nvidia, Abbvie, ConocoPhillips and Vertex Pharma
The Investment Committee share their top stocks to watch for the second half.
Final Trades: Nvidia, Abbvie, ConocoPhillips and Vertex Pharma
The Investment Committee share their top stocks to watch for the second half.
06/14 03:03 EST - businesswire.com
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel [exa-cel]) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, presented at the annual European Hematology Association (EHA) Congress, confirm the transformative, consistent and durable clinical benefits of CASGEVY over time. CASGEVY is the first and only approved.
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel [exa-cel]) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, presented at the annual European Hematology Association (EHA) Congress, confirm the transformative, consistent and durable clinical benefits of CASGEVY over time. CASGEVY is the first and only approved.
06/13 18:05 EST - globenewswire.com
Vortex Energy Corp. Announces Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, June 13, 2024 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) announces that it intends to complete a non-brokered private placement financing (the “Private Placement”) of up to 4,000,000 units of the Company (the “Units”) at a price of $0.25 per Unit for aggregate gross proceeds of up to $1,000,000. Each Unit shall consist of one common share (each a “Share”) and one common share purchase warrant (each a “Warrant”), with each Warrant entitling the holder thereof to purchase a Share at an exercise price of $0.30 for a period of 24 months from the date of issuance.
Vortex Energy Corp. Announces Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, June 13, 2024 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) announces that it intends to complete a non-brokered private placement financing (the “Private Placement”) of up to 4,000,000 units of the Company (the “Units”) at a price of $0.25 per Unit for aggregate gross proceeds of up to $1,000,000. Each Unit shall consist of one common share (each a “Share”) and one common share purchase warrant (each a “Warrant”), with each Warrant entitling the holder thereof to purchase a Share at an exercise price of $0.30 for a period of 24 months from the date of issuance.
06/12 18:50 EST - zacks.com
Vertex Pharmaceuticals (VRTX) Stock Declines While Market Improves: Some Information for Investors
Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $475.79, signifying a -1.19% move from its prior day's close.
Vertex Pharmaceuticals (VRTX) Stock Declines While Market Improves: Some Information for Investors
Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $475.79, signifying a -1.19% move from its prior day's close.
06/12 10:06 EST - zacks.com
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.